S 23 Magnus

Catalogue entry: S 23 Magnus. Labelled content: 10 mg/tablet. Listed pack: 60 tablets. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

S-23 is an experimental nonsteroidal androgen-receptor modulator. Although it shares a broad research category with Andarine and Ligandrol, its experimental programme has included reproductive suppression as well as anabolic tissue endpoints. Those are important features of its identity, not peripheral details.

What the research measured

Jones and colleagues reported a preclinical male-contraception study in Endocrinology in 2009. The work used rats and examined reproductive outcomes within a defined experimental regimen. It does not establish an effective or reversible contraceptive effect in people, nor does it provide a clinical safety assessment for sporting use.

Sporting claims and limitations

Claims about strength, muscular appearance or avoiding androgen-related effects should be separated from what this animal experiment measured. Hormone suppression and fertility effects are central uncertainties. Reported reversibility in an experimental animal model cannot be converted into a guarantee for a human consumer. Regulatory warnings about the broader SARM class also describe liver and cardiovascular concerns.

Product identity and documentation

The declared content above is a packaging quantity, not an evidence-based administration amount. Product assessment requires confirmation that the material is actually S-23 and that an analytical report belongs to the supplied lot. A name shared with a research paper is insufficient. Pay particular attention to unexplained blends or label substitutions, because they prevent even a basic comparison between the catalogue record and studied material.